Targeted therapy for dermatofibrosarcoma protuberans
- 58 Downloads
Dermatofibrosarcoma protuberans (DFSP) is a rare, cutaneous tumor characterized by aggressive local invasion. Local recurrence after excision is common, especially when negative margins are not achieved. DFSP frequently exhibits translocation of chromosomes 17 and 22, t(17;22). This rearrangement fuses the collagen type Ià1 (COL1A1) gene to the platelet-derived growth factor B-chain (PDGFB) gene. The resultant chimeric gene causes unregulated expression of platelet-derived growth factor leading to abnormal activation of the platelet-derived growth factor receptor (PDGFR) â tyrosine kinase through an autocrine loop. This is believed to be the critical event in DFSP tumorigenesis. Imatinib mesylate is a potent inhibitor of several protein tyrosine kinases, including the PDGFRs. Clinical evidence suggests that imatinib mesylate is a safe and effective treatment in DFSP, especially in cases of recurrent or metastatic disease. Three phase II, multicenter clinical trials are open to further investigate the role of imatinib mesylate in DFSP.
KeywordsImatinib Protein Tyrosine Kinase Imatinib Mesylate Negative Margin Wide Local Excision
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 3.Pedeutour F, Coindre JM, Sozzi G, et al.: Supernumerary ring chromosomes containing chromosome 17 sequences: a specific feature of Dermatofibrosarcoma protuberans? Cancer Genet Cytogenet 1994, 76:1–9. A historically significant article, one of the first to propose an association between specific cytogenetic abnormalities and DFSP.PubMedCrossRefGoogle Scholar
- 9.Simon MP, Navarro M, Roux D, Pouysségur J: Structural and functional analysis of a chimeric protein COL1A1-PDGFB generated by the translocation t(17;22)(q22;q13.1) in Dermatofibrosarcoma protuberans (DP). Oncogene 2001, 20:2965–2975. This elegant experiment shows that the protein in DFSP generated by t(17;22) is identical in structure and function to that which is produced from the ring chromosome.PubMedCrossRefGoogle Scholar
- 10.Sirvent N, Maire G, Pedeutour F: Genetics of dermatofibrosarcoma protuberans family of tumors: from ring chromosomes to tyrosine kinase inhibitor treatment. Genes Chromosomes Cancer 2003, 37:1–19. A very good review of DFSP molecular genetics and recommended reading for anyone interested in targeted therapy for the disease.PubMedCrossRefGoogle Scholar
- 19.McArthur GA, Demetri GD, van Oosterom A, et al.: Molecular and clinical analysis of locally advanced Dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol 2005, 23:866–873. A landmark article, representing the first substantial collection of patients with advanced DFSP to be treated with imatinib. High rates of response were demonstrated.PubMedCrossRefGoogle Scholar
- 38.Imatinib mesylate in treating patients with locally recurrent or metastatic Dermatofibrosarcoma protuberans (DFSP) or transformed fibrosarcomatous DFSP. Accessible at http://www.clinicaltrials.gov/ct/show/NCT00084630Google Scholar
- 39.Imatinib mesylate in treating patients with locally advanced or metastatic Dermatofibrosarcoma protuberans or giant cell fibroblastoma. Accessible at http://www. clinicaltrials.gov/ct/show/NCT00085475Google Scholar